Maximizing Options to Advance Informed Choice for HIV Prevention (MOSAIC) is a five-year (2021–2026) global project funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID) to help adolescent girls and young women and other women prevent HIV by accelerating introduction and scale-up of new and emerging biomedical prevention products.

MOSAIC works across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide range of local partners to perform essential functions that support the introduction of HIV prevention products.

The MOSAIC consortium is led by FHI 360 along with core partners Wits Reproductive Health and HIV Institute (Wits RHI), Pangaea Zimbabwe AIDS Trust (PZAT), LVCT Health, Jhpiego, and AVAC. Local partner leadership and engagement, particularly in sub-Saharan Africa, is intrinsic to the project’s approach to expediting women’s access to new HIV prevention products. The work is also supported by technical partners from Afton Bloom, Avenir Health, Columbia University, Mann Global Health, RTI International, The AIDS Support Organization (TASO), 2Stories, the University of Pittsburgh, and the University of Washington.

Working closely with product developers, MOSAIC will advance access to and uptake within a multi-product market that includes options such as oral pre-exposure prophylaxis (oral PrEP), the dapivirine ring (also called PrEP ring), and injectable long-acting cabotegravir (CAB PrEP). Priority countries for the consortium’s work are Botswana, Eswatini, Kenya, Lesotho, Namibia, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe.

Project Objective and Approach

MOSAIC’s objective is to accelerate introduction and scale-up of new biomedical prevention products and expedite their availability, acceptance, uptake, and impact in PEPFAR programs to help adolescent girls and young women and other women prevent HIV and other infectious diseases. To achieve this objective, MOSAIC works in alignment with five strategic priorities:
The CATALYST Study
Catalyzing access to new prevention products to stop HIV (CATALYST) is MOSAIC’s flagship product introduction study. The goal is to characterize and assess the implementation of an enhanced service delivery package providing choice of oral PrEP, PrEP ring, and CAB PrEP among women at PEPFAR delivery sites in Kenya, Lesotho, South Africa, Uganda, and Zimbabwe. The CATALYST study also uses quality improvement methods to refine components and identify a core service delivery package for PrEP choice.

Meaningful Youth Engagement
The MOSAIC NextGen Squad is a team of paid youth advocates under the age of 30 from MOSAIC countries. This dynamic team of young people shape and participate in MOSAIC project activities with mentorship from local implementing partners and a global support team. The NextGen Squad holds MOSAIC accountable as the project aligns its plans, actions, and monitoring, evaluation, and learning efforts to be responsive to young people’s needs, preferences, and lived experiences; be inclusive of the diversity of adolescent girls and young women; and meaningfully engage young people in research and research utilization.

What MOSAIC Means for Women
Our vision is that after five years, women in sub-Saharan Africa will have access to multiple effective PrEP products that meet their changing needs and desires; that health systems will be enabled to support informed choice and effective use through policies, programming, and differentiated service delivery; and that cost, impact, and targeting guidance will be in place to support efficient use of resources.

For more information about MOSAIC, please contact:

- Kristine Torjesen, MOSAIC Project Director, FHI 360: ktorjesen@fhi360.org
- Ashley Vij, USAID/Office of HIV/AIDS: avij@usaid.gov